Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2013 Apr;93(4):299-301. doi: 10.1038/clpt.2012.236.

Phenotypic vs. target-based drug discovery for first-in-class medicines.

Author information

1
Institute for Rare and Neglected Diseases Drug Discovery, Mountain View, California, USA. david.swinney@irnd3.org

Abstract

Current drug discovery strategies include both molecular and empirical approaches. The molecular approaches are predominantly hypothesis-driven and are referred to as target-based. The empirical approaches are referred to as phenotypic because they rely on phenotypic measures of response. A recent analysis revealed the phenotypic approaches to be the more successful strategy for small-molecule, first-in-class medicines. The rationalization for this success was the unbiased identification of the molecular mechanism of action (MMOA).

PMID:
23511784
DOI:
10.1038/clpt.2012.236
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center